Report Description of the APAC Depression Treatment Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for APAC Depression Treatment Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the APAC Depression Treatment Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

APAC Depression Treatment Market Analysis Executive Summary

Depression and anxiety disorders are the most common psychiatric disorders affecting a huge population across the globe. Depression; is related to a state of emotion that further affects actions, thoughts and sometimes the sleeping pattern of the concerned person. Depression is the most common type of mental disorder affecting nearly 350 million patients of varied scale age groups, whereas, anxiety is a reaction to stress. Extreme level of anxiety result in anxiety disorders which include phobias, obsessive-compulsive disorder, panic disorder, post-traumatic based stress disorder.

Market Size and Key Findings

The APAC Depression Treatment Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.



Market Dynamics

Market Growth Drivers Analysis

With the growing age, individuals go through a number of stress conditions. Some of which are common to all age groups, while some are old-age specific such as loss in capabilities to function properly. In addition, the elder people experience reduced socioeconomic status with retirement, which worsen the situation as it leads to isolation and loneliness. Thus, the older people are more vulnerable toward mental disorders, such as anxiety and depression. Thus, the rising cases of anxiety and depression in elderly population, across the world, would help the anxiety and depression treatment market growth. The awareness about mental diseases has increased across the world, owing to the increased initiatives taken by private and public healthcare institutions.

Market Restraints

Although technology is booming in every sector possible still there is lack of awareness of mental disorders and treatments in most of the developing nations hinders the growth of the depression screening market.

COVID-19 impact on APAC Depression Treatment Market

The pandemic of COVID 19 has not only affected the physical well-being of individuals, but it affected the psychological aspects also. Prolonged physical distance associated with social isolation, collective grief, the virus itself are some of the major side effects of COVID 19 which everyone has to face and it has put a negative impact on the minds of the people. Because of COVID 19, unemployment has also increased many times which not only affects the financial position but also affects emotionally. These are the few reasons which lead to mental disorders and hence depression.

Competitive Landscape

Key Players

The anxiety and depression treatment market has the presence of various key players, such as Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Eli Lilly and Company, GlaxoSmithKline plc., and Sanofi.

Products in Pipeline

• In March 2021, Cipla Limited announced that it has received the approval for its Abbreviated New Drug Application (ANDA) for sumatriptan nasal spray, 20 mg, from the United States Food and Drug Administration (USFDA). It is a generic therapeutic equivalent version of GlaxoSmithKline plcs Imitrex nasal spray, a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for the acute treatment of migraine, with or without aura, in adults.


• In December 2020, H. Lundbeck A/S announced the acceptance of its filing for Vyepti (eptinezumab-jjmr) by the European Medicines Agency (EMA) for Marketing Authorization Application (MAA) review. The filing seeks approval to introduce Vyepti to European citizens who live with migraine and are eligible for preventative therapy. Vyepti is designed to prevent calcitonin gene-related peptide (CGRP) from binding to its receptor, thereby preventing migraine attacks.

Notable Recent Deals

Mergers and acquisitions allow pharmaceutical companies to increase their portfolios, expand their reach, and enhance their workflow, in the anxiety and depression treatment market. Also, several key players are involved in mergers and acquisitions to accelerate the pace of drug discovery and development, in order to gain a competitive edge. For instance, in December 2020, Novartis AG announced to enter into an agreement to acquire Cadent Therapeutics. The acquisition will add two new drugs, which include CAD-9303, a NMDAr positive allosteric modulator; and MIJ-821, a NMDAr negative allosteric modulator, which are in clinical trial stage in the formers portfolio for neurology and psychiatry. Thus, these development strategies will create a diverse portfolio of depression and anxiety drugs in the market, leading to more demand for such drugs.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The impetus for the research stems from the rising prevalence and cost of Major Depressive Disorder (MDD) in the Asia-Pacific. MDD is a collection of symptoms, which vary at an individual level. Recognition of this reality, and applying the appropriate response, would be a great start. The policy recommendations are primarily along the following three themes:

• Enforcing nationwide standards for MDD educational campaigns so as to improve understanding driving more conversations through youths and influencers, requiring employers (public and private) to offer the requisite levels of support, and utilizing platforms for scale such as by establishing Depression Day.


• Providing sustainable coverage to shift toward proper MDD diagnosis and treatment ensuring national planning cycles account for the MDD spectrum, and formalizing the recognition of caregivers and families who are supporting people living with MDD.


• Deploying new models of care that are a more effective and efficient use of resources empowering the use of digital tools in the MDD care systems, reorganizing treatment pathways to reflect a patient-centric mindset, and staying at the forefront of novel interventions.